アデプタス・ヘルス

 ADPTのチャート


 ADPTの企業情報

symbol ADPT
会社名 Adeptus Health Inc (アデプタス・ヘルス)
分野(sector)   
産業(industry)   
業種    医療関連(Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名
代表者役職名
電話番号
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA
終値(lastsale)
時価総額(marketcap)
時価総額
売上高
企業価値(EV)
当期純利益
決算概要
symbol ADPT
会社名 Adeptus Health Inc (アダプティブ・バイオテクノロジーズ(Adaptive Biotechnologies Corp))
分野(sector)   
産業(industry)   
業種 バイオテクノロジー & メディカル リサーチ   医療関連 (Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名 Chad M. Robins
代表者役職名 Executive Chairman Chief Executive Officer Co-Founder
電話番号 +1 206-659-0067
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) -70.60000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 4567.03600
売上高 売上高(百万ドル) 85.07100
企業価値(EV) 企業価値(EV)(百万ドル) 4026.77700
当期純利益 当期純利益(百万ドル) -69.57000
決算概要 BRIEF: For the fiscal year ended 31 December 2019 Adaptive Biotechnologies Corp revenues increased 53% to $85.1M. Net loss applicable to common stockholders increased 50% to $69.6M. Revenues reflect Development revenue increase of 83% to $41.6M Sequencing revenue increase of 32% to $43.5M. Higher net loss reflects Research and development - Balancing increase of 84% to $66.8M (expense).

 ADPTのテクニカル分析


 ADPTのニュース

   FDA approves new COVID test that could help ‘long haulers’  2021/03/09 19:09:46 New York Post
The Food and Drug Administration has issued an emergency use authorization for a new coronavirus testing method using the body’s T-cells — which could help better diagnose COVID long-haulers. The T-Detect COVID-19 test — developed by Seattle-based Adaptive Biotechnologies Corp. in collaboration with Microsoft — is billed as a “next generation” screening method that analyzes…
   Thinking about buying stock in Adaptive Biotechnologies, Immunovant, Salarius Pharmaceuticals, Humanigen, or Remark Holdings? - Stocks News Feed  2021/03/08 14:31:00 Stocks News Feed
NEW YORK, March 8, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for ADPT, IMVT, SLRX, HGEN, and MARK. To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver’s… Read More »Thinking about buying stock in Adaptive Biotechnologies, Immunovant, Salarius Pharmaceuticals, Humanigen, or Remark Holdings?
   Adaptive Biotechnologies beats forecast with $30.2M in Q4 revenue  2021/02/25 18:00:00 BioWorld
Adaptive Biotechnologies Corp. posted revenue of $30.2 million for the fourth quarter of 2020, up 25% from the corresponding prior year period. The tally beat consensus by $3.3 million. Clinical sequencing volume grew 41% to 4,539 clinical tests, compared with the fourth quarter of 2019. For the full year, revenue increased 16% year over year to $98.4 million, and clinical sequencing volume topped out at 15,216 clinical tests delivered, up 50%. The results coincided with the launch of the company’s T-Detect COVID, the first clinical T cell-based test to confirm recent or prior COVID-19 infection.
   Adaptive Biotechnologies: Q4 Earnings Insights  2021/02/24 17:32:00 Benzinga
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share …
   Adaptive Bio Launches T-Cell Based COVID-19 Tests  2021/02/23 17:42:54 Benzinga
Adaptive Biotechnologies Corp (NASDAQ: ADPT ) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection. T-Detect is currently under review by the FDA for Emergency Use Authorization. Separately, the Company also Full story available on Benzinga.com
   FDA approves new COVID test that could help ‘long haulers’  2021/03/09 19:09:46 New York Post
The Food and Drug Administration has issued an emergency use authorization for a new coronavirus testing method using the body’s T-cells — which could help better diagnose COVID long-haulers. The T-Detect COVID-19 test — developed by Seattle-based Adaptive Biotechnologies Corp. in collaboration with Microsoft — is billed as a “next generation” screening method that analyzes…
   Thinking about buying stock in Adaptive Biotechnologies, Immunovant, Salarius Pharmaceuticals, Humanigen, or Remark Holdings? - Stocks News Feed  2021/03/08 14:31:00 Stocks News Feed
NEW YORK, March 8, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for ADPT, IMVT, SLRX, HGEN, and MARK. To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver’s… Read More »Thinking about buying stock in Adaptive Biotechnologies, Immunovant, Salarius Pharmaceuticals, Humanigen, or Remark Holdings?
   Adaptive Biotechnologies beats forecast with $30.2M in Q4 revenue  2021/02/25 18:00:00 BioWorld
Adaptive Biotechnologies Corp. posted revenue of $30.2 million for the fourth quarter of 2020, up 25% from the corresponding prior year period. The tally beat consensus by $3.3 million. Clinical sequencing volume grew 41% to 4,539 clinical tests, compared with the fourth quarter of 2019. For the full year, revenue increased 16% year over year to $98.4 million, and clinical sequencing volume topped out at 15,216 clinical tests delivered, up 50%. The results coincided with the launch of the company’s T-Detect COVID, the first clinical T cell-based test to confirm recent or prior COVID-19 infection.
   Adaptive Biotechnologies: Q4 Earnings Insights  2021/02/24 17:32:00 Benzinga
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share …
   Adaptive Bio Launches T-Cell Based COVID-19 Tests  2021/02/23 17:42:54 Benzinga
Adaptive Biotechnologies Corp (NASDAQ: ADPT ) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection. T-Detect is currently under review by the FDA for Emergency Use Authorization. Separately, the Company also Full story available on Benzinga.com
   Immune Repertoire Sequencing Market - Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Techn  2020/11/26 09:37:59 OpenPR
An informative study on the Immune Repertoire Sequencing Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and
   Viking Global Investors reduced stake in Adaptive Biotechnologies Corp  2020/11/14 02:30:22 Investing.com
https://www.investing.com/news/stock-market-news/viking-global-investors-reduced-stake-in-adaptive-biotechnologies-corp-2348133
   Adaptive Biotechnologies, GSK inks MRD testing pact  2020/11/11 20:03:26 Seeking Alpha
Adaptive Biotechnologies (ADPT +9.3%) has collaborated with GlaxoSmithKline to use its clonoSEQ Assay to assess minimal residual disease (MRD) in GSK's por
   Vacasa Appoints Chris Terrill and Chad Cohen to Board of Directors  2020/11/11 13:00:00 Business Wire
PORTLAND, Ore.--(BUSINESS WIRE)--Vacasa, North America’s leading vacation rental management company, has added two tenured executives to its board of directors. Former CEO of ANGI Homeservices (Angie’s List)/HomeAdvisor Chris Terrill and CFO of Adaptive Biotechnologies and former CFO of Zillow Group Chad Cohen will join Vacasa’s board as independent directors. “Our independent directors join us at an exciting time for Vacasa,” said CEO Matt Roberts. “Consumer demand for professionally managed v
   Here's how 9 leading drugmakers are racing to develop a new kind of coronavirus treatment despite an early setback  2020/10/27 13:02:00 Business Insider
Summary List Placement In the sprint for an effective coronavirus treatment, several of the biggest drugmakers in the world have all landed on the same strategy. Companies like Regeneron, Eli Lilly, and AstraZeneca are using the body's own disease-fighting proteins, called antibodies, as the source material to develop coronavirus drugs. The leading efforts are now applying for emergency approval, with one even being used experimentally as part of President Donald Trump's COVID-19 treatment regimen. Six programs have started human testing, led by Lilly, Regeneron, Vir Biotechnology, AstraZeneca, Celltrion, and SAB Biotherapeutics. Lilly, Regeneron, Vir, and AstraZeneca are in the final stage of clinical testing. Lilly and Regeneron have both applied for emergency authorization for their drugs from the US Food and Drug Administration. Early human data suggest the treatments can slash the hospitalization rate and help people's immune systems fight the virus. The treatments are still experimental, with none having won regulatory approval for widespread use.

 関連キーワード  (― 米国株 アデプタス・ヘルス ADPT )

 twitter  (公式ツイッターやCEOツイッターなど)